Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months

Status Not yet recruiting

Clinical Trial Summary

Belatacept inhibits T cell activation by blocking the costimulatory signal. In kidney transplantation, it limits the use of anticalcineurins (1) while ensuring a satisfactory level of immunosuppression. The Rouen strategy consists of offering belatacept to kidney transplant patients presenting with clinical and biological intolerance to anticalcineurins with histological toxicity. This strategy improves or stabilizes the graft glomerular filtration rate (GFR) in patients with precarious renal function. However, we observed a high incidence of opportunistic infections (12.1%), mainly due to CMV, in elderly patients whose GFR is <25ml/min. 2/3 of CMV infections occur in the year following the introduction of belatacept, can be particularly severe and involve the vital prognosis of the patients as well as that of the graft. They led us to carry out systematic antiviral prophylaxis for 3 months with Valganciclovir as soon as belatacept was introduced. The immune control of CMV depends essentially on effector/memory T cells specific to the virus. The impact of costimulation blockade on certain persistent viral infections has been studied experimentally. It is major when the infection is established but appears variable in the chronic phase depending on the type of virus. The viral load seems to be an element conditioning the size of the antiviral T lymphocyte repertoire as well as its functions (lymphocyte exhaustion). In the case of CMV, the consequences of costimulation blockade on the pool of specific effector/memory T cells are not known. We hypothesize that under belatacept, the weight of CMV on the immune system induces quantitative changes in the pool of effector/memory T cells (inflation or, on the contrary, contraction) and/or its functional exhaustion, likely to lead to a loss control of viral replication. We therefore propose to study the evolution of the anti-CMV response in terms of amplitude, specificity and functionality, after introduction of belatacept in CMV+ patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Kidney Transplant Infection

Clinical Trial Details

NCT number	NCT05708534
Study type	Observational
Source	University Hospital, Rouen
Contact	LAURENT Charlotte
Phone	02 32 88 90 02
Email	charlotte.laurent@chu-rouen.fr
Status	Not yet recruiting
Phase
Start date	May 1, 2023
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02439957` - A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus	Phase 3
Not yet recruiting	`NCT06364618` - Use of Wearables to Detect Infections in Kidney Transplant Recipients
Completed	`NCT05142748` - Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital
Terminated	`NCT05747053` - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed	`NCT03339661` - Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.	Phase 2
Enrolling by invitation	`NCT05224583` - Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant
Recruiting	`NCT04701528` - Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients	Phase 2
Recruiting	`NCT04494776` - SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
Completed	`NCT02263703` - Immunogenicity of HPV Vaccine in Immunosuppressed Children	Phase 3
Recruiting	`NCT06219616` - Prediction of BK Virus Reactivation in Kidney Transplant Recipient	N/A
Recruiting	`NCT03488771` - Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
Recruiting	`NCT04815954` - Early vs Late Urinary Catheter Removal After Renal Transplantation	N/A
Recruiting	`NCT05727709` - Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients
Completed	`NCT04542954` - Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
Active, not recruiting	`NCT03924219` - CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Recruiting	`NCT05836636` - Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study
Not yet recruiting	`NCT06407232` - Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients	Phase 3
Completed	`NCT03468478` - Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation	Phase 4
Recruiting	`NCT05397821` - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Not yet recruiting	`NCT05316038` - Metabolic and Infectious Complications Post Belatacept Conversion

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept. — VIRABEL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms